{"entity":{"id":"prkcb","kind":"target","name":"PRKCB","aka":["protein kinase C beta","Protein kinase C beta type","PKCβ","PRKCB2","PRKCB1"],"tldr":"PRKCB (Protein kinase C beta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.","summary":"Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signalling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'.\n\nCIViC holds 3 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.86, genetic association 0.00, somatic mutation 0.45, clinical 0.92). IntOGen calls it a driver in 4 cohorts (4 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma, Stomach Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9395","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9395"},{"label":"UniProt P05771","url":"https://www.uniprot.org/uniprotkb/P05771/entry"},{"label":"NCBI Gene 5579","url":"https://www.ncbi.nlm.nih.gov/gene/5579"},{"label":"Ensembl ENSG00000166501","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166501"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["leukaemia","myeloproliferative-neoplasms","head-and-neck","prostate","gastric","systemic-mastocytosis","aml","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.94; IntOGen calls it an activating (Act) driver in 4 cohorts; CIViC holds 3 clinical evidence items on its variants. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Adult T-cell Leukaemia/lymphoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PRKCB","role":["drug-target","oncogene-driver","biomarker"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9395","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9395","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P05771","url":"https://www.uniprot.org/uniprotkb/P05771/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PRKCB","url":"https://civicdb.org/features/4517","note":"3 evidence items, 0 assertions, 2 variants; diseases: Adult T-cell Leukaemia/lymphoma, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000166501","url":"https://platform.opentargets.org/target/ENSG00000166501/associations","note":"association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.60, myeloproliferative neoplasm 0.60, systemic mastocytosis 0.54, leukaemia 0.65 (GraphQL API, CC0)"},{"label":"IntOGen PRKCB","url":"https://www.intogen.org/search?gene=PRKCB","note":"driver in 4 cohorts (Act 4, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:9395","ensembl":"ENSG00000166501","uniprot":"P05771","entrez":"5579","biology":"Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signalling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signalling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localisation and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Location: Cytoplasm; Nucleus; Membrane (UniProt). Locus 16p12.2-p12.1 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.65 with leukaemia (MONDO_0005059)","Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076)","Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)","Prostate cancer: IntOGen driver in 1 cohort (PRAD)","Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)","Systemic mastocytosis: Open Targets association 0.54 with systemic mastocytosis (MONDO_0016586)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/prkcb/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/"}]}}